Yuflyma(Cf) Autoinject (2 Pck) (Adalimumab-Aaty) Patent Expiration, LOE Window & CMS Spending

Yuflyma(Cf) Autoinject (2 Pck) (Adalimumab-Aaty) by Celltrion USA: Off-Patent Genericized (AB Competition), 0 AB generics, $23.7M 2024 CMS Part D & Medicaid spend, and $1,557 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCelltrion USA
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$23.7M
2024 Medicare Part D Spend$22.4M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,557 intro WAC)